TGA to review blood cancer drug amid safety concerns

Clinicians should avoid prescribing the antineoplastic agent idelalisib (Zydelig) as a first line treatment says the TGA following safety concerns with the drug. The advice comes after makers of the drug Gilead Sciences put a halt to several phase 3 trials on Monday after reports of serious adverse events among study participants including infections leading ...

Already a member?

Login to keep reading.

© 2021 the limbic